Fairness opinions › Acquirers
Thoma Bravo: healthcare acquisitions with fairness opinions
2 public-company targets, 2016-2023, $2.3B combined enterprise value. The multiples Thoma Bravo paid and the banker analyses behind each target board's recommendation.
Deals
2
Median EV / EBITDA paid
16.1x
Median EV / revenue paid
3.27x
| Announced | Target | Acquirer | Segment | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|---|
| 2023-09-05 | NextGen Healthcare | Thoma Bravo | Digital / HealthTech | $1.8B | 16.1x | 2.76x | 8.9%–10.6% | Morgan Stanley |
| 2016-07-13 | Imprivata | Thoma Bravo | Digital / HealthTech | $544M | — | 3.78x | 11.0%–15.0% | Barclays |